A Randomized Double-Blind Multi-Center Open-Label Effectiveness Trial of Antidepressant Augmentation in Patients with Treatment Resistant Depression

Brief description of study

The purpose of this research to compare three treatment strategies for patients with Treatment Resistant Depression (TRD): adding the atypical antipsychotic aripiprazole to current antidepressant treatment, adding repetitive transcranial magnetic stimulation (rTMS) to current antidepressant treatment, and switching to the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release or duloxetine for those who have already tried venlafaxine extended release. Repetitive TMS is a way to stimulate parts of the brain with a series of magnetic pulses. It’s non-invasive and the magnetic pulses are painless. All three of these treatments are FDA-approved for major depression, widely available and commonly used in TRD. They are either generic, or covered by Medicare and commercial insurance.


Clinical Study Identifier: s17-00349
ClinicalTrials.gov Identifier: NCT02977299
Principal Investigator: Dan Iosifescu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.